---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003811"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:08:39.762240+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie terminates TREM2 program and collaboration with Alector after Phase 2 miss

## Summary
- INVOKE-2 Phase 2 trial of AL002 in early Alzheimer's disease did not meet primary endpoint (announced Nov 25, 2024).
- AbbVie provided written termination notice on Jan 9, 2025 for TREM2 program and the overall collaboration agreement.
- Termination effective 30 days from receipt of Jan 9 termination letter; no other programs remain in the partnership.
- The TREM2 program was the only remaining program under the AbbVie Agreement, so termination ends the entire collaboration.

## SEC filing metadata
- accession: 0000950170-25-003811
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017025003811/0000950170-25-003811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017025003811/alec-20250109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003811
- JSON: https://secwatch.observer/filing/0000950170-25-003811.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.